These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 37376452)

  • 1. Intranasal Single-Replication Influenza Vector Induces Cross-Reactive Serum and Mucosal Antibodies against SARS-CoV-2 Variants.
    Moser MJ; Hill-Batorski L; Bowen RA; Matejka SM; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    Vaccines (Basel); 2023 Jun; 11(6):. PubMed ID: 37376452
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mucosal immunization with dual influenza/COVID-19 single-replication virus vector protects hamsters from SARS-CoV-2 challenge.
    Hill-Batorski L; Bowen R; Bielefeldt-Ohmann H; Moser MJ; Matejka SM; Marshall D; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2024 Apr; 42(11):2770-2780. PubMed ID: 38508930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intranasal M2SR (M2-Deficient Single Replication) H3N2 Influenza Vaccine Provides Enhanced Mucosal and Serum Antibodies in Adults.
    Eiden J; Fierro C; Schwartz H; Adams M; Ellis KJ; Aitchison R; Herber R; Hatta Y; Marshall D; Moser MJ; Belshe R; Greenberg H; Coelingh K; Kawaoka Y; Neumann G; Bilsel P
    J Infect Dis; 2022 Dec; 227(1):103-112. PubMed ID: 36350017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. M2SR, a novel live influenza vaccine, protects mice and ferrets against highly pathogenic avian influenza.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2017 Jul; 35(33):4177-4183. PubMed ID: 28668565
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longevity and Mechanism of Heterosubtypic Protection Induced by M2SR (M2-Deficient Single-Replication) Live Influenza Virus Vaccine in Mice.
    Sarawar S; Gabaglia CR; Sanchez A; Hatta Y; Dias P; Neumann G; Kawaoka Y; Bilsel P
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intranasal administration of adenoviral vaccines expressing SARS-CoV-2 spike protein improves vaccine immunity in mouse models.
    Freitag TL; Fagerlund R; Karam NL; Leppänen VM; Ugurlu H; Kant R; Mäkinen P; Tawfek A; Jha SK; Strandin T; Leskinen K; Hepojoki J; Kesti T; Kareinen L; Kuivanen S; Koivulehto E; Sormunen A; Laidinen S; Khattab A; Saavalainen P; Meri S; Kipar A; Sironen T; Vapalahti O; Alitalo K; Ylä-Herttuala S; Saksela K
    Vaccine; 2023 May; 41(20):3233-3246. PubMed ID: 37085458
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity.
    Hatta Y; Boltz D; Sarawar S; Kawaoka Y; Neumann G; Bilsel P
    Vaccine; 2018 Aug; 36(33):5097-5103. PubMed ID: 30007825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants.
    Wang Q; Yang C; Yin L; Sun J; Wang W; Li H; Zhang Z; Chen S; Liu B; Liu Z; Shi L; Liu X; Guan S; Wang C; Qu L; Feng Y; Niu X; Feng L; Zhao J; Li P; Chen L; Zhong N
    Signal Transduct Target Ther; 2023 Apr; 8(1):167. PubMed ID: 37069171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal M2SR (M2-deficient Single Replication) Influenza Vaccine Induces Broadly Reactive Mucosal Antibody Production in Adults.
    Hill-Batorski L; Weiner JA; Ackerman ME; Hatta Y; Hoft DF; Herber R; Moser MJ; Bilsel P
    J Infect Dis; 2024 Jul; ():. PubMed ID: 39012796
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Bacteriophage-Based, Highly Efficacious, Needle- and Adjuvant-Free, Mucosal COVID-19 Vaccine.
    Zhu J; Jain S; Sha J; Batra H; Ananthaswamy N; Kilgore PB; Hendrix EK; Hosakote YM; Wu X; Olano JP; Kayode A; Galindo CL; Banga S; Drelich A; Tat V; Tseng CK; Chopra AK; Rao VB
    mBio; 2022 Aug; 13(4):e0182222. PubMed ID: 35900097
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quadrivalent Formulation of Intranasal Influenza Vaccine M2SR (M2-Deficient Single Replication) Protects against Drifted Influenza A and B Virus Challenge.
    Hill-Batorski L; Hatta Y; Moser MJ; Sarawar S; Neumann G; Kawaoka Y; Bilsel P
    Vaccines (Basel); 2023 Apr; 11(4):. PubMed ID: 37112710
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.
    Nguyen KG; Mantooth SM; Vrabel MR; Zaharoff DA
    Front Immunol; 2022; 13():858904. PubMed ID: 35592324
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
    Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
    Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An intranasal influenza virus-vectored vaccine prevents SARS-CoV-2 replication in respiratory tissues of mice and hamsters.
    Deng S; Liu Y; Tam RC; Chen P; Zhang AJ; Mok BW; Long T; Kukic A; Zhou R; Xu H; Song W; Chan JF; To KK; Chen Z; Yuen KY; Wang P; Chen H
    Nat Commun; 2023 Apr; 14(1):2081. PubMed ID: 37045873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced mucosal immune responses and reduced viral load in the respiratory tract of ferrets to intranasal lipid nanoparticle-based SARS-CoV-2 proteins and mRNA vaccines.
    Boley PA; Lee CM; Schrock J; Yadav KK; Patil V; Suresh R; Lu S; Feng MM; Hanson J; Channappanavar R; Kenney SP; Renukaradhya GJ
    J Nanobiotechnology; 2023 Feb; 21(1):60. PubMed ID: 36814238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mucosal immunization with Ad5-based vaccines protects Syrian hamsters from challenge with omicron and delta variants of SARS-CoV-2.
    Braun MR; Martinez CI; Dora EG; Showalter LJ; Mercedes AR; Tucker SN
    Front Immunol; 2023; 14():1086035. PubMed ID: 36911687
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and immunogenicity of a live-attenuated influenza virus vector-based intranasal SARS-CoV-2 vaccine in adults: randomised, double-blind, placebo-controlled, phase 1 and 2 trials.
    Zhu F; Zhuang C; Chu K; Zhang L; Zhao H; Huang S; Su Y; Lin H; Yang C; Jiang H; Zang X; Liu D; Pan H; Hu Y; Liu X; Chen Q; Song Q; Quan J; Huang Z; Zhong G; Chen J; Han J; Sun H; Cui L; Li J; Chen Y; Zhang T; Ye X; Li C; Wu T; Zhang J; Xia NS
    Lancet Respir Med; 2022 Aug; 10(8):749-760. PubMed ID: 35644168
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of Systemic and Mucosal Humoral Immune Responses to an Adjuvanted Intranasal SARS-CoV-2 Protein Subunit Vaccine Candidate in Mice.
    Maltseva M; Galipeau Y; Renner TM; Deschatelets L; Durocher Y; Akache B; Langlois MA
    Vaccines (Basel); 2022 Dec; 11(1):. PubMed ID: 36679875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection.
    Du L; Zhao G; Lin Y; Sui H; Chan C; Ma S; He Y; Jiang S; Wu C; Yuen KY; Jin DY; Zhou Y; Zheng BJ
    J Immunol; 2008 Jan; 180(2):948-56. PubMed ID: 18178835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.